Versant Venture Capital Vi, L.P. Aligos Therapeutics, Inc. (ALGS) insider trading activity

Versant Venture Capital Vi, L.P. is > 10% Shareholder of Aligos Therapeutics, Inc.. Currently has a direct ownership of 2.43 Million shares of ALGS, which is worth approximately $106 Million. The most recent transaction as insider was on Oct 20, 2020, when has been sold 2,429,895 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.43M

0% 3M change

0% 12M change

Total Value Held $106 Million

Versant Venture Capital VI, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Oct 20 2020	BUY Conversion of derivative security	-	2,429,895 Added 50.0%	2,429,895 Common Stock

Also insider at

BDTX

Black Diamond Therapeutics, Inc. Healthcare

OYST

Oyster Point Pharma, Inc. Healthcare

> 10% Shareholder

IPSC

Century Therapeutics, Inc. Healthcare

> 10% Shareholder

GLUE

Monte Rosa Therapeutics, Inc. Healthcare

GRPH

Graphite Bio, Inc. Healthcare

CTNM

Contineum Therapeutics, Inc.

> 10% Shareholder

TPST

Tempest Therapeutics, Inc. Healthcare

VVC